| __timestamp | Pfizer Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14097000000 | 504755000 |
| Thursday, January 1, 2015 | 14809000000 | 838526000 |
| Friday, January 1, 2016 | 14837000000 | 1177697000 |
| Sunday, January 1, 2017 | 14784000000 | 1320433000 |
| Monday, January 1, 2018 | 14455000000 | 1556200000 |
| Tuesday, January 1, 2019 | 14350000000 | 1834800000 |
| Wednesday, January 1, 2020 | 11615000000 | 1346000000 |
| Friday, January 1, 2021 | 12703000000 | 1824900000 |
| Saturday, January 1, 2022 | 13677000000 | 2115900000 |
| Sunday, January 1, 2023 | 14771000000 | 2631300000 |
| Monday, January 1, 2024 | 14730000000 | 2954400000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Pfizer Inc. and Regeneron Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually. In contrast, Regeneron has seen a significant increase, with expenses growing by over 400% from $505 million in 2014 to $2.63 billion in 2023.
This trend highlights Pfizer's consistent cost management strategy, while Regeneron's rising expenses may reflect its aggressive growth and expansion efforts. As the pharmaceutical industry continues to evolve, understanding these financial dynamics provides valuable insights into each company's operational efficiency and strategic priorities.
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Pfizer Inc. vs GSK plc
Who Optimizes SG&A Costs Better? Pfizer Inc. or Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Mesoblast Limited
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Merus N.V.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.